F3Logic’s Agios Pharmaceuticals AGIO Stock Holding History

F3Logic’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	-$1.75K	–	225
2020 Q3	$1.75K	Buy	+50	New	+$2.19K	0.04%	241

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

F3Logic's AGIO Position: Q4 2020 in Review

F3Logic sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 50 shares — an estimated $1.75K sold.

F3Logic first reported a position in AGIO in Q3 2020 and held it in 1 quarter. The position peaked at $1.75K in Q3 2020. 200 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

F3Logic reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
F3Logic sold 50 Agios Pharmaceuticals shares in Q4 2020, an estimated $1.75K.
F3Logic first reported a position in Agios Pharmaceuticals in Q3 2020 and held it in 1 quarter.
F3Logic's Agios Pharmaceuticals position peaked at $1.75K in Q3 2020.
200 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on F3Logic's 13F filing for Q4 2020, filed 12 Feb 2021.